|
| Press Releases |
|
 |
|
| Monday, April 27, 2026 |
|
|
康哲藥業就已上市原研藥靜脈鐵劑莫諾菲和科莫非簽訂獨家商業化與供應協議 |
| 康哲藥業控股有限公司（867.HK/8A8.SG）（"康哲藥業"）欣然宣佈，近期，康哲藥業通過其全資附屬公司與Pharmacosmos A/S就異麥芽糖酐鐵注射液（"莫諾菲(R)"）和右旋糖酐鐵注射液（"科莫非(R)"）簽訂獨家商業化與供應協議（"協議"）。 more info >> |
|
|
康哲药业就已上市原研药静脉铁剂莫诺菲和科莫非签订独家商业化与供应协议 |
| 康哲药业控股有限公司（867.HK/8A8.SG）（"康哲药业"）欣然宣布，近期，康哲药业通过其全资附属公司与Pharmacosmos A/S就异麦芽糖酐铁注射液（"莫诺菲(R)"）和右旋糖酐铁注射液（"科莫非(R)"）签订独家商业化与供应协议（"协议"）。 more info >> |
|
|
CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R) |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the "Agreement") with Pharmacosmos A/S for Iron Isomaltoside Injection ("Monofer(R)") and Iron Dextran Injection ("Cosmofer(R)") recently. more info >> |
|
| Thursday, April 23, 2026 |
|
|
CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, "MG-K10" or the "Product"), a Class 1 innovative drug anti-IL-4Ra humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. more info >> |
|
|
康哲藥業：1類新藥MG-K10季節性過敏性鼻炎適應症NDA獲受理 |
| 康哲藥業控股有限公司（「康哲藥業」）（867.HK; 8A8.SG）欣然宣佈，其擁有共同開發權（除特應性皮炎（AD）外）及獨家商業化權利的1類新藥抗IL-4Rα人源化單抗注射液MG-K10（通用名為柯美奇拜單抗注射液，「MG-K10」或「產品」）季節性過敏性鼻炎適應症中國上市許可申請（NDA）於2026年4月23日獲得中國國家藥品監督管理局（NMPA）受理。產品擬用於鼻用糖皮質激素治療後症狀控制不佳的成人中重度季節性過敏性鼻炎患者。 more info >> |
|
|
康哲药业：1类新药MG-K10季节性过敏性鼻炎适应症NDA获受理 |
| 康哲药业控股有限公司（"康哲药业"）（867.HK; 8A8.SG）欣然宣布，其拥有共同开发权（除特应性皮炎（AD）外）及独家商业化权利的1类新药抗IL-4Rα人源化单抗注射液MG-K10（通用名为柯美奇拜单抗注射液，"MG-K10"或"产品"）季节性过敏性鼻炎适应症中国上市许可申请（NDA）于2026年4月23日获得中国国家药品监督管理局（NMPA）受理。产品拟用于鼻用糖皮质激素治疗后症状控制不佳的成人中重度季节性过敏性鼻炎患者。 more info >> |
|
| Friday, March 20, 2026 |
|
|
康哲藥業業績拐點確立：創新藥與獨家藥接棒增長 新藥進入密集兌現期 |
| 康哲藥業（0867.HK）發佈2025年度業績公告，全面展現戰略轉型成效。 more info >> |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China |
| more info >> |
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China |
| China Medical System Holdings Limited ("CMS", or the "Group") is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the "Product") has been approved for marketing in China by the National Medical Products Administration of the People's Republic of China (NMPA). more info >> |
|
|
康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市 |
| 康哲藥業控股有限公司(867.HK/8A8.SG)（「康哲藥業」）欣然宣佈，腎性貧血新藥德昔度司他片（原名：德度司他片）（「產品」）上市許可申請已於2026年3月13日獲得中國國家藥品監督管理局（NMPA）批准。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
ZOQQ 憑藉自力更生的發展模式逐步邁向收支平衡——打破「先燒錢再盈利」的金融科技慣例
May 5, 2026 07:00 HKT/SGT
|
|
|
ZOQQ在自力更生的道路上接近盈亏平衡——打破“先烧钱”的金融科技惯例
May 5, 2026 07:00 HKT/SGT
|
|
|
ZOQQ Approaches Breakeven on a Bootstrapped Path - Bucking the Burn-First Fintech Playbook
May 5, 2026 07:00 HKT/SGT
|
|
|
TaxiNexo Accelerates Global Expansion: Autonomous Taxis Arrive in Los Angeles
May 4, 2026 23:30 HKT/SGT
|
|
|
TaxiNexo Accelerates Global Expansion: Autonomous Taxis Arrive in Los Angeles
May 4, 2026 23:00: JST
|
|
|
As bossware backlash grows, Vaiz launches work management built on trust, not tracking
May 4, 2026 23:00: JST
|
|
|
As bossware backlash grows, Vaiz launches work management built on trust, not tracking
May 4, 2026 23:00 HKT/SGT
|
|
|
Pacific Avenue Capital Partners 就收購 ESE World（Amcor 旗下歐洲廢棄物容器業務）進入獨家談判
May 4, 2026 21:00 HKT/SGT
|
|
|
Pacific Avenue Capital Partners 就收购 ESE World（Amcor 旗下欧洲废弃物容器业务）进入独家谈判
May 4, 2026 21:00 HKT/SGT
|
|
|
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business
May 4, 2026 16:30: JST
|
|
|
Pacific Avenue Capital Partners、Amcorの欧州廃棄物容器事業「ESE World」の買収に向けた独占交渉を開始
May 4, 2026 16:30: JST
|
|
|
Pacific Avenue Capital Partners Enters into Exclusive Negotiations to Acquire ESE World, Amcor's European Waste Container Business
May 4, 2026 15:30 HKT/SGT
|
|
|
6 Ways to Get More Rewards and Experiences from Everyday Spending
May 4, 2026 14:00 HKT/SGT
|
|
|
Breaking Through 'Chokepoint' Technology: China Risun's Hexamethylenediamine Plant Commenced Production
May 4, 2026 11:53 HKT/SGT
|
|
|
The 16th PropertyGuru Asia Property Awards (Singapore) introduces new categories as market adapts in 2026
May 4, 2026 11:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
